Novel Method of Treating Cancer Using Ixolaris

Aggressive tumors spread between tissues in a process known as metastasis. Tumor metastasis, particularly with regard to brain cancer (gliomas), has been linked to the aberrant expression of membrane-bound tissue factor (TF). TF normally functions as a blood coagulation factor and can lead to the production of pro-angiogenesis factors such as vascular endothelial growth factor (VEGF). By doing this in the vicinity of tumors, TF may enhance both tumor growth and the ability of tumors to metastasize.

Ixolaris is a protein that prevents the initiation of blood coagulation, specifically by inhibiting TF. NIH inventors have explored the possibility that Ixolaris could be effective as an anti-cancer therapy. As an inhibitor of TF, Ixolaris could potentially inhibit the function of TF, thereby reducing the ability of a tumor to develop and to metastasize. Recent data show that Ixolaris has the ability to prevent tumor growth in vivo using mouse xenograft models. Importantly, the inhibition in vivo occurred without noticeable bleeding. Since Ixolaris is not immunogenic, it might be an excellent candidate as an anti-cancer therapeutic.

Potential Commercial Applications: Competitive Advantages:
Treatment and prevention of tumor growth and metastasis by inhibiting TF and blood vessel formation   Provides a novel mechanism for preventing tumor metastasis

Ivo Francischetti (NIAID)
Robson Monteiro
Jose Ribeiro (NIAID)

Intellectual Property:
US Application No. 61/161,223
US Application No. 61/225,961

US Patent 7,078,508 entitled "Ixodes Scapularis Tissue Factor Pathway Inhibitor"
IM Francischetti et al. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002 May 15;99(10):3602-3612. PubMed: 11986214
RA Nazareth et al. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. Thromb Haemost. 2006 Jul;96(1):7-13. PubMed: 16807644

Collaboration Opportunity:

The NIAID, OTD, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Ixolaris for cancer treatment. Please contact Dana Hsu at 301-496-2644 for more information.

Licensing Contact:
Patrick McCue , Ph.D.
NIH Office of Technology Transfer
Phone: 301-496-7057

OTT Reference No: E-148-2009/0

Updated: Jun-16-2010